European Union - English - EMA (European Medicines Agency)

eurocept international b. v. - para-aminosalicylic acid - tuberculosis - antimycobacterials - granupas is indicated for use as part of an appropriate combination regimen for multi-drug resistant tuberculosis in adults and paediatric patients from 28 days of age and older when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see section 4.4).consideration should be given to official guidance on the appropriate use of antibacterial agents.

United States - English - NLM (National Library of Medicine)

jacobus pharmaceutical company, inc. - aminosalicylic acid (unii: 5b2658e0n2) (aminosalicylic acid - unii:5b2658e0n2) - aminosalicylic acid 4 g - paser is indicated for the treatment of tuberculosis in combination with other active agents. it is most commonly used in patients with multi-drug resistant tb (mdr-tb) or in situations when therapy with isoniazid and rifampin is not possible due to a combination of resistance and/or intolerance. when paser is added to the treatment regimen in patients proven or suspected drug resistance, it should be accompanied by at least one and preferably two other new agents to which the patient's organism is known or expected to be susceptible. hypersensitivity to any component of this medication. severe renal disease. patients with severe renal disease will accumulate aminosalicylic acid and its acetyl metabolite but will continue to acetylate, thus leading exclusively to the inactive acetylated form; deacetylation, if any, is not significant. the half life of free aminosalicylic acid in renal disease is 30.8 minutes in comparison to 26.4 minutes in normal volunteers. but the half life of the inactive metabolite is 30

Israel - English - Ministry of Health

truemed ltd, israel - 4 - aminosalicylic acid - gastro resistant granules - 4 - aminosalicylic acid 4 g/sachet - 4-aminosalicylic acid - granupas is indicated for use as part of an appropriate combination regimen for multi-drug resistant tuberculosis in adults and paediatric patients from 28 days of age and older when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.

Australia - English - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - paracetamol, quantity: 10 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; mannitol; sodium hydroxide; dibasic sodium phosphate dihydrate; povidone - paracetamol bnm 1000mg/100ml, solution for infusion is indicated for the relief of mild to moderate pain and the reduction of fever where an intravenous route of administration is considered clinically necessary.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 30 mg - tablet, uncoated - excipient ingredients: potassium sorbate; maize starch; povidone; purified talc; stearic acid; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; pregelatinised maize starch - paracetamol/codeine gh 500/30 is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - paracetamol - solution for infusion - paracetamol 10 mg/ml - paracetamol - paracetamol – fresenius is indicated for:- the short-term treatment of moderate pain, especially following surgery- the short-term treatment of fever.when administration by intravenous route is clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible.

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - paracetamol - solution for infusion - paracetamol 10 mg/ml - paracetamol - paracetamol – fresenius is indicated for:- the short-term treatment of moderate pain, especially following surgery- the short-term treatment of fever.when administration by intravenous route is clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible.

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - paracetamol - solution for infusion - paracetamol 10 mg/ml - paracetamol - paracetamol – fresenius is indicated for:- the short-term treatment of moderate pain, especially following surgery- the short-term treatment of fever.when administration by intravenous route is clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible.

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - paracetamol - solution for infusion - paracetamol 10 mg/ml - paracetamol - paracetamol – fresenius is indicated for:- the short-term treatment of moderate pain, especially following surgery- the short-term treatment of fever.when administration by intravenous route is clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible.

Israel - English - Ministry of Health

raz pharmaceutics ltd, israel - paracetamol - solution for infusion - paracetamol 10 mg / 1 ml - paracetamol - paracetamol is indicated for the short-term treatment of moderate pain, especially following surgery and for the short-term treatment of fever, when intravenous administration is clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible.